Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$1.61 - $5.2 $442,009 - $1.43 Million
-274,540 Closed
0 $0
Q4 2021

Mar 03, 2022

BUY
$2.87 - $6.29 $752,611 - $1.65 Million
262,234 Added 2130.94%
274,540 $831,000
Q3 2021

Nov 15, 2021

BUY
$4.91 - $9.07 $60,422 - $111,615
12,306 New
12,306 $77,000

Others Institutions Holding BCEL

About Atreca, Inc.


  • Ticker BCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,876,000
  • Description
  • Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...
More about BCEL
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.